Tecarfarin sodium

Tecarfarin (0.5 mg/kg; p.o.; once daily; for 6 consecutive days) sodium selectively reduces the levels of vitamin K-dependent coagulation factors in female beagle dogs and prolongs PT by 3.1-fold^[1].
Tecarfarin (0.05-0.5 mg/kg; p.o.; daily; 4-7 days) sodium increases the arterial occlusive thrombosis time and venous occlusive thrombosis time by 57% and 119%, respectively, in mongrel dogs with electrically injured and stenotic blood vessels^[1].
Tecarfarin (1 mg/kg; p.o.; once daily; for 2 consecutive days) sodium increases the INR to 2.1 in New Zealand white rabbits, and reduces venous thrombosis rates by 89% (radioactive method) and 82% (weighing method), respectively, with no statistically significant increase in bleeding compared with the normal saline control group^[1].
Tecarfarin (0.1-0.2 mg/kg; intravenous injection; continuous infusion; administered for 9 days per course) sodium produces a dose-dependent anticoagulant effect in beagle dogs^[3].
Tecarfarin (0.05-0.3 mg/kg; p.o.; twice daily or once daily; 10-21 days) sodium administered once daily produces dose-dependent anticoagulant effects in beagle dogs^[3].
Tecarfarin (0.5 mg/kg; p.o.; once daily; for 4 consecutive days) sodium induces stable anticoagulant effects in beagles, and these effects can be completely reversed by intravenous infusion of fresh frozen plasma or subcutaneous injection of vitamin K₁^[3].
Tecarfarin (0.3 mg/kg or dose-adjusted; oral administration; once daily; for 20 consecutive days) sodium induces stable anticoagulant effects in beagle dogs when dosed to maintain PT at 15-30 s, and its anticoagulant efficacy and plasma levels are not affected by co-administration with Amiodarone (HY-14187)^[3].